Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.8900 (5.73%) ($10.8900 - $10.8900) on Sat. Oct. 21, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.99% (three month average) | RSI | 48 | Latest Price | $10.8900(5.73%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.9% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting FOLD price | FOLD will decline at least -1.495% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.495% (StdDev 2.99%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
Resistance Level | $11.08 | 5 Day Moving Average | $10.63(2.45%) | 10 Day Moving Average | $10.63(2.45%) | 20 Day Moving Average | $11.08(-1.71%) | To recent high | -21% | To recent low | 7.7% | Market Cap | $N/A | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |